In this article, we will look at the 10 Best Healthcare Stocks to Buy for the Long Term.
On May 7, Haig Bathgate, CEO of Callanish Capital, appeared on CNCB to talk about his bullish view on the global markets amid the Iran war, and how its impact would be short-lived, especially when compared to the bigger and long-term worries for the market, such as concerns over capex spend and the AI boom.
He was of the view that we should always look back into history, as it is very easy to get swayed by and caught up in the emotions of what is happening in the short term. The reality, he stated, is that wars have a very limited long-term impact on stock markets. While we will see some effects, with some sectors affected more than others, the long-term impact is usually relatively short-lived, which is why he is trying to look through that.
READ ALSO: 10 Best Performing Healthcare Stocks So Far in 2026 AND 10 Best Strong Buy Stocks to Invest in According to Billionaires.
Bathgate further stated that before we entered into this war, the US stock markets had been accelerating into the tail end of last year. Therefore, he is trying to assess the long-term nature of what happens with AI, energy supply, and long-term drivers of underlying profitability in the markets, which is driven by things that are very different from what we are seeing in the Middle East at the moment.
With these broader market trends in view, let’s narrow down and look at the best healthcare stocks to buy for the long term.
Our Methodology
We used the Finviz stock screener to identify the best high-growth healthcare stocks with a forward P/E below 15 and selected the top 10 stocks most popular among hedge funds as of Q4 2025, using the hedge fund sentiment data from Insider Monkey’s database. The stocks are arranged in ascending order of hedge fund sentiment.
Note: All data was recorded on May 8.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
10 Best Healthcare Stocks to Buy for the Long Term
10. AdaptHealth Corp. (NASDAQ:AHCO)
Number of Hedge Fund Holders: 22
AdaptHealth Corp. (NASDAQ:AHCO) is one of the best healthcare stocks to buy for the long term. Canaccord lifted the price target on AdaptHealth Corp. (NASDAQ:AHCO) to $16 from $14 on May 7, reiterating a Buy rating on the shares. The firm updated its model after the company released its fiscal Q1 results, where EBITDA missed estimates and caused a pullback in the shares. It added that AdaptHealth Corp. (NASDAQ:AHCO) appears to be uniquely positioned in the DME market to gain share, especially if the demand environment for capitated agreements becomes the preferred method to better serve patients with chronic conditions.
AdaptHealth Corp. (NASDAQ:AHCO) released its fiscal Q1 2026 results on May 5, with net revenue for the quarter coming up to $819.8 million compared to $777.9 million, reflecting an increase of 5.4%. The company also reported organic revenue growth of 9.1%, with growth across each of the reportable segments. Net loss attributable to the company was $16.0 million.
AdaptHealth Corp. (NASDAQ:AHCO) provides home healthcare equipment, supplies, and related services. The company’s focus is on sleep therapy equipment for obstructive sleep apnea, oxygen, and related chronic therapy services, HME medical devices and supplies for wound care, diabetes, urological, and more.
9. Phibro Animal Health Corporation (NASDAQ:PAHC)
Number of Hedge Fund Holders: 25
Phibro Animal Health Corporation (NASDAQ:PAHC) is one of the best healthcare stocks to buy for the long term. Phibro Animal Health Corporation (NASDAQ:PAHC) announced on May 6 financial results for its third quarter ended March 31, 2026, along with updated financial guidance for the year ending June 30, 2026. The company reported net sales of $383.5 million for the quarter, reflecting an increase of $35.7 million, or 10%, from the prior year period. Net income reached $24.0 million, an increase of $3.1 million, or 15%, with diluted earnings per share of $0.59, an increase of $0.08, or 16% from the prior year period.
Phibro Animal Health Corporation (NASDAQ:PAHC) attributed the positive results to continued strength in the company’s Animal Health business, where sales rose 13%, backed by strong demand across MFAs, vaccines, and nutritional specialties. The company also updated its fiscal year 2026 guidance, which includes net sales of $1.46 billion to $1.50 billion and adjusted EBITDA of $247 million to $255 million.
Phibro Animal Health Corporation (NASDAQ:PAHC) develops, manufactures, and markets animal health and mineral nutrition products. Its operations are divided into the following segments: Animal Health, Mineral Nutrition, and Performance Products.
8. Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Number of Hedge Fund Holders: 31
Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the best healthcare stocks to buy for the long term. Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced on May 7 that the company entered into a global collaboration and license agreement with GSK, under which GSK has licensed Halozyme’s ENHANZE® drug delivery technology for the development and potential commercialization of subcutaneous administration of multiple oncology targets. This includes antibody drug conjugates (ADCs), as well as an option for additional future drug targets.
Eric Richards, SVP Head of Medicine Development Leaders Oncology, GSK, said that they “see significant potential for subcutaneous formulations of several promising cancer targets, including ADCs, with ENHANZE and look forward to progressing the first clinical program”.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) further reported that GSK will make an upfront payment to Halozyme and potential future milestone payments, and Halozyme will also be entitled to royalties on net sales of products that incorporate ENHANZE®. In a separate development, H.C. Wainwright lifted the price target on Halozyme Therapeutics, Inc. (NASDAQ:HALO) to $95 from $90 on April 29, maintaining a Buy rating on the shares.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a biopharmaceutical technology platform company that develops, manufactures, and commercializes drug-device combination products through advanced auto-injector technology. They offer commercial or functional benefits, including increased patient comfort and adherence, and enhanced tolerability and convenience.
7. Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)
Number of Hedge Fund Holders: 37
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is one of the best healthcare stocks to buy for the long term. Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) announced financial results for fiscal Q1 2026 on May 7, reporting net product revenue of $215.4 million for the quarter, delivering 17% year‑over‑year growth, and on track for full year 2026 net revenues of over $1 billion. Management stated that performance in the quarter highlighted continued strong demand, offset by market access headwinds that are observed every Q1 and were especially “pronounced” this year. In addition, the cost of product sold was $44.5 million, or 20.7% as a percentage of net product revenue, as compared to $32.0 million, or 17.3%, for the prior year period, reflecting a 39% increase.
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) further stated that it is continuing to vigorously protect WAKIX IP into 2030 and filed a suit against AET Pharma/Sandoz regarding the infringement of the amorphous pitolisant patent. The company also received FDA approval of pediatric cataplexy indication on February 13th, and the commercial team initiated full promotional efforts immediately upon approval.
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is a commercial-stage pharmaceutical company that develops and commercializes therapies to treat neurological disorders. Its product, WAKIX, is a molecule that increases histamine signaling in the brain by binding to H3 receptors.
6. ADMA Biologics Inc. (NASDAQ:ADMA)
Number of Hedge Fund Holders: 38
ADMA Biologics Inc. (NASDAQ:ADMA) is one of the best healthcare stocks to buy for the long term. Canaccord cut the price target on ADMA Biologics Inc. (NASDAQ:ADMA) to $18 from $21 on May 7, reiterating a Buy rating on the shares. The firm told investors that fiscal Q1 2026 was a reset quarter for the company, with results falling short and guidance lowered primarily because of pressure on Bivigam within the standard IG market. It added that it is important to note that the key product and value driver, Asceniv, held up pretty well in fiscal Q1.
The rating update came after ADMA Biologics Inc. (NASDAQ:ADMA) reported its fiscal Q1 2026 earnings on May 6, with total revenue of $114.5 million, flat year-over-year. ASCENIV revenue for the quarter rose 28% year-over-year, while BIVIGAM revenue dropped 54% year-over-year. Management further reported that adjusted net income for fiscal Q1 2026 was $40.7 million, up 22% year-over-year, while adjusted EBITDA reached $59.7 million, reflecting a 24% year-over-year growth.
ADMA Biologics Inc. (NASDAQ:ADMA) is a biopharmaceutical company that manufactures, markets, and develops specialty plasma-derived biologics. Its operations are divided into the following business segments: ADMA BioManufacturing and Plasma Collection Center.
While we acknowledge the potential of ADMA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ADMA and that has 100x upside potential, check out our report about the cheapest AI stock.
Click to continue reading and see the 5 Best Healthcare Stocks to Buy for the Long Term.
Disclosure: None. Follow Insider Monkey on Google News.
